Courier Capital LLC Has $1.64 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Courier Capital LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,616 shares of the medical instruments supplier’s stock after selling 211 shares during the quarter. Courier Capital LLC’s holdings in Becton, Dickinson and Company were worth $1,637,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. DiNuzzo Private Wealth Inc. acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $30,000. Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Finally, Fortitude Family Office LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $233.71 on Friday. The stock has a market capitalization of $67.54 billion, a price-to-earnings ratio of 51.48, a PEG ratio of 2.03 and a beta of 0.44. Becton, Dickinson and Company has a 52-week low of $224.00 and a 52-week high of $287.32. The stock’s 50 day moving average price is $234.36 and its two-hundred day moving average price is $237.84. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.86 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock worth $2,033,381 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent analyst reports. Barclays increased their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.